No single person discovered non-Hodgkin’s lymphoma. The category emerged gradually over more than a century, defined not by what it is but by what it is not: any lymphoma that lacks the hallmark features of Hodgkin’s disease. The story begins with Thomas Hodgkin himself in 1832 and then branches outward through dozens of pathologists, virologists, and molecular biologists who identified the many distinct cancers lumped under the non-Hodgkin umbrella.
Thomas Hodgkin and the Disease That Got a Name
In 1832, the British physician Thomas Hodgkin published a paper titled “On some morbid appearances of the absorbent glands and spleen,” describing seven patients with massively enlarged lymph nodes and spleens. His observations were the first to single out a specific disease of the lymphatic system, distinguishing it from infections like tuberculosis that could also cause swollen glands.1PubMed Central. Thomas Hodgkin: medical immortal and uncompromising idealist Decades later, Samuel Wilks independently described additional cases, confirmed Hodgkin’s original findings, and proposed that the disease bear Hodgkin’s name. By the late 1800s, “Hodgkin’s disease” was an established diagnosis.
That naming act had an enormous unintended consequence. Once pathologists could identify Hodgkin’s disease under the microscope, they began noticing that many other lymph-node cancers did not match Hodgkin’s pattern. These cancers looked different, behaved differently, and responded differently to treatment. They had no unifying name of their own. For decades they were simply “the lymphomas that aren’t Hodgkin’s,” and eventually that awkward negative definition stuck: non-Hodgkin’s lymphoma.
The Reed-Sternberg Cell and the Line in the Sand
The critical diagnostic dividing line between Hodgkin’s disease and everything else came down to a single, unmistakable cell. In the early 1900s, Dorothy Reed and Carl Sternberg independently described giant multinucleated cells found in Hodgkin’s tissue. These Reed-Sternberg cells, surrounded by a characteristic background of inflammatory cells, became the defining feature of what is now called classical Hodgkin lymphoma. If a biopsy contained them in that typical inflammatory setting, it was Hodgkin’s; if not, it was non-Hodgkin’s.
The distinction is not always clean. Reed-Sternberg-like cells occasionally show up in non-Hodgkin lymphomas too, scattered as isolated cells or in small clusters rather than within the dense inflammatory backdrop seen in classical Hodgkin lymphoma.2PubMed Central. Reed Sternberg-Like Cells in Non-Hodgkin Lymphoma: A Diagnostic Challenge These look-alikes can mislead pathologists, which is why modern diagnosis relies on additional markers beyond cell shape alone. But the Reed-Sternberg cell remains the historical and practical anchor that separates the two broad families of lymphoma.
Early Subtypes Begin to Emerge
Even before the non-Hodgkin category had a formal name, researchers were identifying specific lymphoma subtypes that would eventually fall under it. In 1925, Nathan Brill and Douglas Symmers independently described a slow-growing lymphoma with a distinctive follicular, or nodular, growth pattern. Initially believed to be benign, Brill-Symmers disease was soon recognized as a true malignancy with a variable but often indolent course.3PubMed. Follicular lymphoma: a historical overview Today we call it follicular lymphoma, and it remains one of the most common non-Hodgkin subtypes.
Three decades later, Denis Burkitt described a jaw tumor affecting children in central Africa. His 1958 clinical report established Burkitt’s lymphoma as a distinct entity.4PubMed. Epstein-Barr virus and the pathogenesis of Burkitt’s lymphoma: more questions than answers The unusual geographic clustering of Burkitt’s cases, concentrated in the tropical “lymphoma belt” of equatorial Africa, hinted that an infectious agent might be involved. That hunch turned out to be spectacularly productive.
Viruses Enter the Picture
Burkitt’s geographic observations launched one of the most consequential virus hunts in cancer biology. In 1964, Anthony Epstein, Yvonne Barr, and Bert Achong identified a new herpesvirus in cell cultures derived from Burkitt’s lymphoma tissue. Epstein-Barr virus, as it became known, was the first virus convincingly linked to a human cancer.4PubMed. Epstein-Barr virus and the pathogenesis of Burkitt’s lymphoma: more questions than answers The relationship between EBV and Burkitt’s lymphoma is still not fully understood. EBV infects the vast majority of the world’s population, yet Burkitt’s lymphoma is rare. Malaria co-infection, immune suppression, and specific chromosomal rearrangements all appear to play a role in pushing EBV-infected cells toward malignancy.
A second viral discovery came in the late 1970s and early 1980s. Robert Gallo’s laboratory in the United States identified human T-cell leukemia virus type 1 (HTLV-1) in 1979, publishing characterization of the virus in 1980. This was the first pathogenic human retrovirus ever found.5PubMed Central. The discovery of HTLV-1, the first pathogenic human retrovirus Collaboration with Japanese researchers who had independently identified a cluster of adult T-cell leukemia cases confirmed that HTLV-1 caused this aggressive T-cell malignancy, which falls within the non-Hodgkin lymphoma family.6Oncogene. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2 HTLV-1 infection remains endemic in parts of Japan, the Caribbean, and sub-Saharan Africa, and only a small fraction of infected individuals develop the associated lymphoma, often decades after initial infection.
A Bacterium That Causes Lymphoma
Not all lymphoma-causing infections are viral. In the 1990s, researchers established a link between the common stomach bacterium Helicobacter pylori and a type of non-Hodgkin lymphoma arising in the stomach lining, known as gastric MALT lymphoma. This was a paradigm-shifting finding: a lymphoma that grew in response to chronic bacterial infection and, in many cases, could be treated simply by eliminating the bacteria with antibiotics. Eradication of H. pylori is successful in roughly 60 to 80 percent of affected patients, making this one of the few cancers where the initial treatment is an antibiotic course rather than chemotherapy or radiation.7PubMed. Helicobacter pylori and mucosa-associated lymphoid tissue: what’s new When antibiotic therapy fails, molecular abnormalities in the tumor cells are often the reason, and those patients require more conventional cancer treatment.8PubMed Central. Molecular Aspects of H. pylori-Related MALT Lymphoma
Sorting the Chaos With Immune Cell Biology
By the 1970s, the non-Hodgkin category had become a grab-bag of cancers that looked and behaved very differently from one another. Some grew slowly over years; others killed within weeks. Some started in lymph nodes; others appeared in the stomach, skin, or brain. Pathologists had proposed competing classification systems, often disagreeing on which features mattered most.
A breakthrough came when researchers began classifying lymphomas based on which type of immune cell had turned malignant. The recognition that the immune system’s lymphocytes come in two major lineages, T cells and B cells, allowed a new functional classification that grouped lymphomas by their cell of origin and the stage of cell development at which transformation occurred.9PubMed Central. New approaches to the classification of the lymphomata This was a genuine conceptual leap. Instead of sorting lymphomas purely by how they looked under a microscope, researchers could now connect each cancer to a specific type of immune cell gone wrong. The vast majority of non-Hodgkin lymphomas turned out to arise from B cells, with a smaller proportion originating from T cells or natural killer cells.
In 1994, an international group of pathologists proposed a consensus classification that tried to unify the competing systems by listing lymphoid cancers as distinct clinicopathological entities, each defined by a combination of microscopic appearance, immune markers, genetic features, and clinical behavior.10PubMed. A proposal for classification of lymphoid neoplasms This framework evolved into the World Health Organization classification, which is now the global standard and recognizes more than 80 distinct subtypes of lymphoid cancers. Each revision incorporates new molecular and genetic information, meaning the list continues to grow.
Molecular Discoveries That Redefined Subtypes
Some of the most important “discoveries” within non-Hodgkin lymphoma were not of new diseases but of the molecular events driving diseases already known. Follicular lymphoma, the slow-growing cancer first described by Brill and Symmers, was found in the 1980s to be driven by a specific chromosomal rearrangement. The translocation swaps pieces of chromosomes 14 and 18, placing a gene called bcl-2 next to the machinery that normally drives antibody production. The result is that the bcl-2 gene, which blocks programmed cell death, gets switched on permanently. The cancer cells refuse to die on schedule.11Cell. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation Molecular studies confirmed this translocation in virtually all follicular lymphomas and about 28 percent of diffuse large B-cell lymphomas, suggesting a deep genetic link between these seemingly different cancers.12PubMed. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas
Burkitt’s lymphoma, meanwhile, was found to be driven by a different translocation involving the MYC gene on chromosome 8. This rearrangement supercharges cell growth and division.13PubMed Central. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management The MYC translocation gives cancer cells a proliferative advantage through heightened cell division, evasion of programmed death, and metabolic reprogramming.14Lymphatics. Translocation Tales: Unraveling the MYC Deregulation in Burkitt Lymphoma for Innovative Therapeutic Strategies Detection of this translocation, combined with gene expression profiling, has become central to distinguishing true Burkitt’s lymphoma from other aggressive B-cell lymphomas that can look similar under the microscope.15PubMed. Molecular diagnosis of Burkitt’s lymphoma
These molecular findings transformed diagnosis from an exercise in pattern recognition to one grounded in the specific genetic event that launched each cancer. Two tumors that look identical under the microscope can carry different translocations, respond to different treatments, and have very different prognoses.
Gene Expression Profiling Splits Diseases Further
Diffuse large B-cell lymphoma (DLBCL) is the single most common type of non-Hodgkin lymphoma. For years it was treated as one disease, even though some patients responded well to chemotherapy while others did not. In the early 2000s, gene expression profiling revealed the reason: DLBCL is actually at least two distinct diseases wearing the same name. One subtype, called germinal center B-cell-like DLBCL, expresses genes normally active in the part of the lymph node where B cells mature. The other, called activated B-cell-like DLBCL, expresses genes typical of B cells that have been stimulated outside the germinal center. Patients with the germinal center subtype have a substantially better prognosis after standard chemotherapy.16PubMed. Gene expression profiling of diffuse large B-cell lymphoma Researchers developed methods to assign individual biopsies to one subgroup or the other based on patterns across hundreds of genes.17PubMed Central. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
This kind of molecular subtyping has implications that go well beyond prognosis. Clinical trials now often enroll patients by subtype, and newer targeted therapies are designed to exploit the specific vulnerabilities of each molecular group. The broader lesson is that “non-Hodgkin’s lymphoma” was never really one disease to discover. It was a filing cabinet for dozens of distinct cancers, and researchers are still pulling new folders out of it.
Rituximab and the Treatment Revolution
Understanding what non-Hodgkin lymphomas are made of opened the door to treatments aimed at specific molecular targets. The most transformative was rituximab, a laboratory-engineered antibody designed to latch onto a protein called CD20, which sits on the surface of most B cells and, by extension, most B-cell lymphomas. Rituximab was approved by the U.S. Food and Drug Administration in 1997 for indolent forms of non-Hodgkin lymphoma, making it the first monoclonal antibody approved for any cancer.18PubMed Central. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
Rituximab changed survival curves for several common non-Hodgkin subtypes when added to standard chemotherapy. Its success also proved a concept: that antibodies targeting specific surface markers on cancer cells could work in the real world, not just in the lab. The drug paved the way for a generation of targeted and immunological therapies for blood cancers, including newer antibodies, antibody-drug conjugates, and engineered T-cell treatments that have followed in its footsteps.19PubMed Central. Rituximab for non-Hodgkin’s lymphoma: a story of rapid success in translation
Why Dogs Matter to This Story
One of the more unexpected chapters in non-Hodgkin lymphoma research involves domestic dogs. Lymphoma is the most common blood cancer in dogs, and the canine disease shares striking similarities with the human version, not just in how the tumors look under the microscope but in the molecular abnormalities that drive them.20PubMed. The dog as a possible animal model for human non-Hodgkin lymphoma: a review The full range of lymphoma subtypes seen in people also occurs in dogs, with conserved genetic features that make canine lymphoma a natural model for the human disease.
Dogs develop lymphoma spontaneously rather than having it induced in a laboratory, which makes their disease a closer parallel to what happens in human patients. They also have compressed life spans relative to humans, meaning researchers can observe disease progression and treatment responses in months rather than years. This has made dogs valuable partners in testing new therapies before human clinical trials, accelerating the development pipeline for both species.21PubMed Central. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications The comparative oncology approach benefits veterinary medicine just as much: treatments refined in human trials often loop back to improve care for dogs with the same cancers.
Why No One Gets Sole Credit
The question “who discovered non-Hodgkin’s lymphoma” resists a clean answer because the category was never a single discovery. It was assembled, piece by piece, as researchers peeled individual diseases away from a catch-all label. Thomas Hodgkin created the negative space in 1832 by defining the disease that bore his name. Brill and Symmers gave shape to the first recognized non-Hodgkin subtype in 1925. Denis Burkitt identified the tumor that led to the discovery of both EBV and the MYC translocation. Gallo’s laboratory found the first human retrovirus linked to T-cell lymphoma. Pathologists like those in the International Lymphoma Study Group built classification systems that imposed order on a bewildering array of cancers. Molecular biologists identified the genetic switches, like bcl-2 and MYC, that revealed why individual subtypes behave the way they do. And clinician-scientists developed rituximab, turning molecular understanding into treatments that changed patient outcomes.
Each of these contributions redefined what non-Hodgkin lymphoma meant, splitting old categories and revealing new ones. The process is still underway. Every few years, advances in genomics or immunology carve yet another distinct entity out of what was once a single diagnostic line on a pathology report. The “discovery” of non-Hodgkin lymphoma is less a moment than a continuing project, and the disease category itself may eventually be retired in favor of the specific names it has always been a placeholder for.